{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:48:44Z","timestamp":1794019724475,"version":"4.8.0"},"reference-count":77,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Although immune checkpoint inhibitors (ICIs) are increasingly used in patients with preexisting systemic autoimmune rheumatic diseases (SARDs), a key concern is whether baseline immunosuppression at the start of ICI treatment might negatively affect cancer outcomes. This risk must be carefully weighed against the potential for a SARD flare. The objective of this study was to develop a living guideline that will provide up-to-date guidance on the management of baseline immunosuppression for preexisting SARDs when initiating cancer immunotherapy with ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) formed a multidisciplinary panel composed of rheumatologists, oncologists, researchers, and a patient representative, with methodological support from the Canadian Rheumatology Association (CRA). We completed a systematic literature review to inform this first installment of our living guideline. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, the panel developed recommendations for the management of baseline immunosuppression in individuals with preexisting SARDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 67 publications that reported on immunosuppression and cancer outcomes by specific preexisting rheumatic diseases, including 36 on preexisting SARD. Eight best practice statements were developed, highlighting the importance of shared decision making between patients and their care team and careful consideration of risk of SARD flare, risk of organ- or life-threatening manifestations, and potential effect of immunosuppression on cancer outcomes. Seven specific recommendations were made, 1 each for preexisting systemic lupus erythematosus, systemic sclerosis, Sj\u00f6gren disease, myositis, sarcoidosis, vasculitis, and Beh\u00e7et disease, considering both the available evidence and expert consensus. The general recommendation for preexisting SARDs was to continue baseline immunosuppression, particularly if there are organ- or life-threatening manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting SARDs when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.rheum.ca\">www.rheum.ca<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.canrio.ca\">www.canrio.ca<\/jats:ext-link>\n                      ). (PROSPERO registration: CRD42023461024)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0482","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T12:25:20Z","timestamp":1757939120000},"page":"1218-1230","source":"Crossref","is-referenced-by-count":6,"title":["Canadian Rheumatology Association\/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-5398","authenticated-orcid":false,"given":"Carrie","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4199-733X","authenticated-orcid":false,"given":"Roko P.A.","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-2737","authenticated-orcid":false,"given":"May","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-9825","authenticated-orcid":false,"given":"Aurore Viviane","family":"Fifi-Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8771-6815","authenticated-orcid":false,"given":"Jeffrey","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5580-6472","authenticated-orcid":false,"given":"Liam J.","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7503-123X","authenticated-orcid":false,"given":"Alexandra","family":"Kobza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-6597","authenticated-orcid":false,"given":"Keith C.K.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3624-1194","authenticated-orcid":false,"given":"Lourdes Gonzalez","family":"Arreola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-5335","authenticated-orcid":false,"given":"Jordi Pardo","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3755-4860","authenticated-orcid":false,"given":"Alexandra","family":"Ladouceur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0962-9003","authenticated-orcid":false,"given":"Alexandra","family":"Saltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Velthuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4721-2559","authenticated-orcid":false,"given":"Faiza","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-8334","authenticated-orcid":false,"given":"Ines","family":"Colmegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-8541","authenticated-orcid":false,"given":"Janet","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-2468","authenticated-orcid":false,"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1561-7026","authenticated-orcid":false,"given":"Megan","family":"Himmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8535-4312","authenticated-orcid":false,"given":"Nancy","family":"Maltez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-5729","authenticated-orcid":false,"given":"Sabrina","family":"Hoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-3741","authenticated-orcid":false,"given":"Glen S.","family":"Hazlewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5870-3567","authenticated-orcid":false,"given":"Shahin","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2025120106151113000_52.12.1218.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190084"},{"key":"2025120106151113000_52.12.1218.2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025120106151113000_52.12.1218.3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025120106151113000_52.12.1218.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2025120106151113000_52.12.1218.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217139"},{"key":"2025120106151113000_52.12.1218.6","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073"},{"key":"2025120106151113000_52.12.1218.7","unstructured":"MAGICapp . Guidelines. [Internet. Accessed August 6, 2025.] Available from: https:\/\/app.magicapp.org\/#\/guidelines\/mine=1&org=cra"},{"key":"2025120106151113000_52.12.1218.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0481"},{"key":"2025120106151113000_52.12.1218.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2019.10.014"},{"key":"2025120106151113000_52.12.1218.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025120106151113000_52.12.1218.11","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3419"},{"key":"2025120106151113000_52.12.1218.12","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1136\/annrheumdis-2023-eular.6448","article-title":"AB1768-HPR Safety and efficacy of immune checkpoint inhibitors in patients with rheumatic autoimmune disease: experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) [abstract]","volume":"82","author":"Gonzalez Arreola","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025120106151113000_52.12.1218.13","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025120106151113000_52.12.1218.14","doi-asserted-by":"crossref","first-page":"e002121","DOI":"10.1136\/jitc-2020-002121","article-title":"Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025120106151113000_52.12.1218.15","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","article-title":"Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology","volume":"70","author":"Hoa","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2025120106151113000_52.12.1218.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2025120106151113000_52.12.1218.17","doi-asserted-by":"crossref","first-page":"113508","DOI":"10.1016\/j.ejca.2023.113508","article-title":"Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma\u2014an analysis of the prospective skin cancer registry ADOREG","volume":"198","author":"Kochanek","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025120106151113000_52.12.1218.18","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025120106151113000_52.12.1218.19","doi-asserted-by":"crossref","first-page":"114172","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025120106151113000_52.12.1218.20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002261"},{"key":"2025120106151113000_52.12.1218.21","doi-asserted-by":"crossref","first-page":"e2340695","DOI":"10.1001\/jamanetworkopen.2023.40695","article-title":"Survival among veterans receiving steroids for immune-related adverse events after immune checkpoint inhibitor therapy","volume":"6","author":"Van Buren","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025120106151113000_52.12.1218.22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0775-4"},{"key":"2025120106151113000_52.12.1218.23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2021.10.018","article-title":"Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: a postmarketed phase IV safety assessment study","volume":"160","author":"Panhaleux","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025120106151113000_52.12.1218.24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0618"},{"key":"2025120106151113000_52.12.1218.25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2025120106151113000_52.12.1218.26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"K\u00e4hler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025120106151113000_52.12.1218.27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025120106151113000_52.12.1218.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102596"},{"key":"2025120106151113000_52.12.1218.29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/iju5.12175","article-title":"Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus","volume":"3","author":"Kurokawa","year":"2020","journal-title":"IJU Case Rep"},{"key":"2025120106151113000_52.12.1218.30","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.21037\/atm-20-8124","article-title":"Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease","volume":"9","author":"Alexander","year":"2021","journal-title":"Ann Transl Med"},{"key":"2025120106151113000_52.12.1218.31","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1093\/rheumatology\/keac106","article-title":"Clinical vignette: paraneoplastic diffuse systemic sclerosis","volume":"61","author":"Nowak","year":"2022","journal-title":"Rheumatology"},{"key":"2025120106151113000_52.12.1218.32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jmv.2016.07.001","article-title":"Paraneoplastic systemic sclerosis: about 3 cases and review of literature","volume":"41","author":"Monfort","year":"2016","journal-title":"J Mal Vasc"},{"key":"2025120106151113000_52.12.1218.33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5114\/reum.2018.76907","article-title":"Paraneoplastic systemic sclerosis associated with colorectal carcinoma","volume":"56","author":"Samotij","year":"2018","journal-title":"Reumatologia"},{"key":"2025120106151113000_52.12.1218.34","first-page":"39","article-title":"Paraneoplastic systemic sclerosis: focus on anti-RNA polymerase III antibodies","volume":"14","author":"Heymann","year":"2016","journal-title":"Skinmed"},{"key":"2025120106151113000_52.12.1218.35","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.40065","article-title":"Brief report: anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma","volume":"69","author":"Shah","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025120106151113000_52.12.1218.36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/RHU.0000000000001863","article-title":"A safety analysis of programmed death 1 pathway inhibitors in patients with solid tumor malignancies and preexisting autoimmune disease","volume":"28","author":"Higgins","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2025120106151113000_52.12.1218.37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/03008916211067565","article-title":"Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease","volume":"108","author":"Spagnoletti","year":"2022","journal-title":"Tumori"},{"key":"2025120106151113000_52.12.1218.38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2217\/imt-2019-0025","article-title":"Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus","volume":"11","author":"Tagliamento","year":"2019","journal-title":"Immunotherapy"},{"key":"2025120106151113000_52.12.1218.39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000538"},{"key":"2025120106151113000_52.12.1218.40","doi-asserted-by":"crossref","first-page":"570752","DOI":"10.3389\/fonc.2020.570752","article-title":"Incidence of skin and respiratory immune-related adverse events correlates with specific tumor types in patients treated with checkpoint inhibitors","volume":"10","author":"Rose","year":"2020","journal-title":"Front Oncol"},{"key":"2025120106151113000_52.12.1218.41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025120106151113000_52.12.1218.42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025120106151113000_52.12.1218.43","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025120106151113000_52.12.1218.44","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00432-021-03610-w","article-title":"Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience","volume":"147","author":"Bhatlapenumarthi","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025120106151113000_52.12.1218.45","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/20009666.2021.1903133","article-title":"Pembrolizumab related Guillain Barre syndrome, a rare presentation in a patient with a history of lupus and bladder cancer","volume":"11","author":"Sangani","year":"2021","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"2025120106151113000_52.12.1218.46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CJI.0000000000000377","article-title":"Safety and clinical outcomes of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases","volume":"44","author":"Yeung","year":"2021","journal-title":"J Immunother"},{"key":"2025120106151113000_52.12.1218.47","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1016\/S1556-0864(21)02050-5","article-title":"208P Safety and efficacy of immune checkpoint inhibitors in NSCLC patients with autoimmune disease: a UK tertiary cancer centre experience","volume":"16","author":"Sawhney","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025120106151113000_52.12.1218.48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221295"},{"key":"2025120106151113000_52.12.1218.49","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101766"},{"key":"2025120106151113000_52.12.1218.50","doi-asserted-by":"crossref","first-page":"e0251731","DOI":"10.1371\/journal.pone.0251731","article-title":"Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy","volume":"16","author":"Krueger","year":"2021","journal-title":"PLoS One"},{"key":"2025120106151113000_52.12.1218.51","doi-asserted-by":"crossref","first-page":"101990","DOI":"10.1016\/j.isci.2020.101990","article-title":"Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models","volume":"24","author":"Wabitsch","year":"2021","journal-title":"iScience"},{"key":"2025120106151113000_52.12.1218.52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2020.07.023","article-title":"Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced\/metastatic urinary tract carcinoma","volume":"138","author":"Loriot","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025120106151113000_52.12.1218.53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/rheumatology\/keae152","article-title":"British Society for Rheumatology guideline on management of adult and juvenile onset Sj\u00f6gren disease","volume":"64","author":"Price","year":"2025","journal-title":"Rheumatology"},{"key":"2025120106151113000_52.12.1218.54","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/odi.14000","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"28","author":"Harris","year":"2022","journal-title":"Oral Dis"},{"key":"2025120106151113000_52.12.1218.55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ajco.13141","article-title":"Immune checkpoint inhibitor use in antisynthetase syndrome","volume":"15","author":"Mackintosh","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025120106151113000_52.12.1218.56","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/CAD.0000000000000661","article-title":"A case of severe pembrolizumab-induced neutropenia","volume":"29","author":"Barbacki","year":"2018","journal-title":"Anticancer Drugs"},{"key":"2025120106151113000_52.12.1218.57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s41927-020-00144-5","article-title":"Pembrolizumab on pre-existing inclusion body myositis: a case report","volume":"4","author":"Uchio","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2025120106151113000_52.12.1218.58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025120106151113000_52.12.1218.59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CJI.0000000000000380","article-title":"Role of IVIG in the treatment of autoimmune conditions with concurrent immune checkpoint inhibitors for metastatic cancer","volume":"44","author":"Punekar","year":"2021","journal-title":"J Immunother"},{"key":"2025120106151113000_52.12.1218.60","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01045-w"},{"key":"2025120106151113000_52.12.1218.61","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40674-022-00197-2","article-title":"Management of cancer-associated myositis","volume":"8","author":"Selva-O\u2019Callaghan","year":"2022","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2025120106151113000_52.12.1218.62","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/imt-2020-0272","article-title":"Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis","volume":"13","author":"Kim","year":"2021","journal-title":"Immunotherapy"},{"key":"2025120106151113000_52.12.1218.63","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3390\/cancers13122931","article-title":"Frequency, treatment and outcome of immune-related toxicities in patients with immune-checkpoint inhibitors for advanced melanoma: results from an institutional database analysis","volume":"13","author":"Dimitriou","year":"2021","journal-title":"Cancers"},{"key":"2025120106151113000_52.12.1218.64","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020"},{"key":"2025120106151113000_52.12.1218.65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/CJI.0000000000000118","article-title":"Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease","volume":"39","author":"Maul","year":"2016","journal-title":"J Immunother"},{"key":"2025120106151113000_52.12.1218.66","first-page":"3428945","article-title":"PD-1 inhibitor therapy in a patient with preexisting P-ANCA vasculitis: a case report and review of the literature","volume":"2020","author":"Ramos","year":"2020","journal-title":"Case Rep Oncol Med"},{"key":"2025120106151113000_52.12.1218.67","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0633"},{"key":"2025120106151113000_52.12.1218.68","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.2169\/internalmedicine.3018-19","article-title":"Non-small cell lung cancer treated by an anti-programmed cell death-1 antibody without a flare-up of preexisting granulomatosis with polyangiitis","volume":"58","author":"Yamada","year":"2019","journal-title":"Intern Med"},{"key":"2025120106151113000_52.12.1218.69","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025120106151113000_52.12.1218.70","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025120106151113000_52.12.1218.71","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1607-y"},{"key":"2025120106151113000_52.12.1218.72","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/cam4.2868","article-title":"PD-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence","volume":"9","author":"Byeon","year":"2020","journal-title":"Cancer Med"},{"key":"2025120106151113000_52.12.1218.73","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","article-title":"Beh\u00e7et syndrome","volume":"7","author":"Yazici","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025120106151113000_52.12.1218.74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225"},{"key":"2025120106151113000_52.12.1218.75","first-page":"23","article-title":"Is apremilast a safe option in patients with history of melanoma? A case series and a review of the literature","volume":"15","author":"Gambardella","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025120106151113000_52.12.1218.76","doi-asserted-by":"crossref","first-page":"1589.2","DOI":"10.1136\/annrheumdis-2022-eular.5218","article-title":"AB0920 Safety of apremilast in PsA patients with history of malignancies or active cancer: a retrospective study [abstract]","volume":"81","author":"Sabella","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025120106151113000_52.12.1218.77","unstructured":"BMJ Best Practice . What is GRADE? [Internet. Accessed August 6, 2025.] Available from: https:\/\/dev-bestpractice.bmjgroup.com\/info\/toolkit\/learn-ebm\/what-is-grade\/"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:16:31Z","timestamp":1764598591000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":77,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.3899\/jrheum.2025-0482"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0482","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}